Gene Therapy for Fanconi Anemia, Complementation Group A
Gene Therapy for Fanconi Anemia, Complementation Group A
Active, not recruiting · NCT04248439 · Registry updated 2025-12-22Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Gene Therapy for Fanconi Anemia, Complementation Group A | Bone Marrow Failure Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Fanconi anemia complementation group A, Fanconi renotubular syndrome, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Hemic and Lymphatic Diseases, Male Urogenital Diseases, Urogenital Diseases, anemia, bone marrow disorder, hematologic disorder, hereditary disease, kidney disorder, renal tubular transport disease, urinary system disorder | Active, not recruiting | Phase 2 | 2025-12-22 | NCT04248439 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Rocket Pharmaceuticals Inc. | 10 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Stanford University | Stanford | United States | 24 |
| University of Minnesota | Minneapolis | United States | 30 |